JP2024129139A5 - - Google Patents

Download PDF

Info

Publication number
JP2024129139A5
JP2024129139A5 JP2024108991A JP2024108991A JP2024129139A5 JP 2024129139 A5 JP2024129139 A5 JP 2024129139A5 JP 2024108991 A JP2024108991 A JP 2024108991A JP 2024108991 A JP2024108991 A JP 2024108991A JP 2024129139 A5 JP2024129139 A5 JP 2024129139A5
Authority
JP
Japan
Prior art keywords
drawings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024108991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024129139A (ja
Filing date
Publication date
Priority claimed from JP2020067797A external-priority patent/JP2020128375A/ja
Application filed filed Critical
Publication of JP2024129139A publication Critical patent/JP2024129139A/ja
Publication of JP2024129139A5 publication Critical patent/JP2024129139A5/ja
Pending legal-status Critical Current

Links

JP2024108991A 2013-08-12 2024-07-05 ベンラリツマブを使用して喘息の増悪率を低減する方法 Pending JP2024129139A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12
US61/864,944 2013-08-12
JP2020067797A JP2020128375A (ja) 2013-08-12 2020-04-03 ベンラリツマブを使用して喘息の増悪率を低減する方法
JP2022092216A JP2022120009A (ja) 2013-08-12 2022-06-07 ベンラリツマブを使用して喘息の増悪率を低減する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022092216A Division JP2022120009A (ja) 2013-08-12 2022-06-07 ベンラリツマブを使用して喘息の増悪率を低減する方法

Publications (2)

Publication Number Publication Date
JP2024129139A JP2024129139A (ja) 2024-09-26
JP2024129139A5 true JP2024129139A5 (https=) 2025-05-26

Family

ID=52448837

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016534614A Active JP6746495B2 (ja) 2013-08-12 2014-08-07 ベンラリツマブを使用して喘息の増悪率を低減する方法
JP2020067797A Withdrawn JP2020128375A (ja) 2013-08-12 2020-04-03 ベンラリツマブを使用して喘息の増悪率を低減する方法
JP2022092216A Pending JP2022120009A (ja) 2013-08-12 2022-06-07 ベンラリツマブを使用して喘息の増悪率を低減する方法
JP2024108991A Pending JP2024129139A (ja) 2013-08-12 2024-07-05 ベンラリツマブを使用して喘息の増悪率を低減する方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2016534614A Active JP6746495B2 (ja) 2013-08-12 2014-08-07 ベンラリツマブを使用して喘息の増悪率を低減する方法
JP2020067797A Withdrawn JP2020128375A (ja) 2013-08-12 2020-04-03 ベンラリツマブを使用して喘息の増悪率を低減する方法
JP2022092216A Pending JP2022120009A (ja) 2013-08-12 2022-06-07 ベンラリツマブを使用して喘息の増悪率を低減する方法

Country Status (26)

Country Link
US (2) US9441037B2 (https=)
EP (1) EP3033101B1 (https=)
JP (4) JP6746495B2 (https=)
KR (2) KR20220057637A (https=)
CN (2) CN105451760A (https=)
AU (2) AU2014306956B2 (https=)
BR (1) BR112016002401A8 (https=)
CA (1) CA2918105C (https=)
CY (1) CY1122132T1 (https=)
DK (1) DK3033101T3 (https=)
ES (1) ES2716906T3 (https=)
HK (1) HK1221644A1 (https=)
HR (1) HRP20190405T1 (https=)
HU (1) HUE042607T2 (https=)
LT (1) LT3033101T (https=)
ME (1) ME03348B (https=)
MX (1) MX368508B (https=)
PL (1) PL3033101T3 (https=)
PT (1) PT3033101T (https=)
RS (1) RS58404B1 (https=)
RU (1) RU2676333C2 (https=)
SG (2) SG10202005560UA (https=)
SI (1) SI3033101T1 (https=)
SM (1) SMT201900163T1 (https=)
TR (1) TR201903312T4 (https=)
WO (1) WO2015023504A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100152T1 (it) 2013-08-12 2021-05-07 Astrazeneca Ab Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab
RU2728578C2 (ru) * 2013-08-12 2020-07-30 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
WO2015057668A1 (en) * 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
CA2926089C (en) * 2013-10-24 2022-08-30 Medimmune, Llc Stable, aqueous antibody formulations
ES2866935T3 (es) 2014-01-10 2021-10-20 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (IL-33)
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
EP3371225A2 (en) 2015-11-04 2018-09-12 AstraZeneca AB Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
EP3565823B1 (en) 2017-01-04 2024-05-29 Worg Pharmaceuticals (Zhejiang) Co., Ltd. S-arrestin peptides and therapeutic uses thereof
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005035583A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Il-5受容体に特異的に結合する抗体組成物
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
MX376656B (es) 2007-05-14 2025-03-07 Kyowa Kirin Co Ltd Metodos para reducir niveles de basófilos.
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
AU2010322066A1 (en) * 2009-11-18 2012-06-21 Medicinova, Inc. Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
RU2578468C2 (ru) 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
WO2012158954A1 (en) 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
US20140328839A1 (en) 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
RU2728578C2 (ru) 2013-08-12 2020-07-30 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
SMT202100152T1 (it) 2013-08-12 2021-05-07 Astrazeneca Ab Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab

Similar Documents

Publication Publication Date Title
JP2025138632A5 (https=)
JP2024116190A5 (https=)
JP2024129139A5 (https=)
JP2025138641A5 (https=)
JP2022191211A5 (https=)
JP2023171775A5 (https=)
JP2023103258A5 (https=)
JP2022184985A5 (https=)
JP2025176106A5 (https=)
JP2024161376A5 (https=)
JP2023166402A5 (https=)
JP2024114921A5 (https=)
JP2024059739A5 (https=)
JP2023518821A5 (https=)
JP2023145572A5 (https=)
JP2025118629A5 (https=)
JP2025160243A5 (https=)
JP2022543046A5 (https=)
JP2026004279A5 (https=)
JP2023181322A5 (https=)
JP2025098156A5 (https=)
JP2024045126A5 (https=)
JP2025090801A5 (https=)
JP2025094038A5 (https=)
JP2024149687A5 (https=)